Andrea Ellis, Director at BridgeBio Pharma, Inc. (BBIO), sold 64,921 shares at $64.87 ($4.2M) on 2026-03-04, disclosed to the SEC on 2026-03-06.
Scheduled sale ($4.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BBIO | SELL | 2025-04-16 | $350K | — | Filing → |
| BBIO | SELL | 2025-04-03 | $2.0M | — | Filing → |
| BBIO | BUY | 2022-03-17 | $101K | — | Filing → |